Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by lovincoalon Mar 10, 2017 4:48pm
140 Views
Post# 25966167

RE:RE:RE:RE:RE:RE:RE:RE:RE:Fear Fongering

RE:RE:RE:RE:RE:RE:RE:RE:RE:Fear Fongeringyes I remember you posting that but why, in your wildest dreams, would you even think it would hit .75
I thought you were just throwing out a random, low # when you mentioned it. I can't believe you actually thought we'd hit that price. If you did believe it, why ? what craziness makes .75 justifiable ? Yes, a crazy market with a crazy seller can distort reality for a brief period of time and that is what we have here. I don't know if this anonymous seller is losing his shirt by selling it down at these prices or if they have cheap paper from long ago and are still making a profit.
I still think the management here should have tracked this seller(s) down and arranged a block trade into hands of believers - the company would be better off and the seller also.
If a placement is being contemplated as several have speculated and posted about, it's destroying the price it should be done at and that dilutes the company more than needed all because of some stupid anonymous selling that could have, imo, been stopped long ago at higher prices.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities